Novo Nordisk faced challenges losing ground in the weight loss market to Eli Lilly last year. However, the company’s oral Wegovy has been approved and launched, showing promising results. The oral version aims to attract patients who prefer not to inject themselves and those who struggle with cold storage requirements.

Novo Nordisk’s strategy with oral Wegovy seems to be effective, with higher prescription volume than the original Wegovy and Eli Lilly’s Zepbound in the first two weeks after launch. While it may not sustain this pace, oral Wegovy could contribute significantly to sales growth, projected to reach $3.3 billion at peak sales.

Despite competition and uncertainties, Novo Nordisk is set to launch more weight-loss medicines, including CagriSema and Amycretin. The company’s deep pipeline and strong product lineup position it well for future revenue and earnings growth. Investors may consider buying Novo Nordisk stock based on its performance and potential in the weight loss market.

Read more at Yahoo Finance: Should You Buy Novo Nordisk Stock on Oral Wegovy’s Strong Launch?